atai Life Sciences (ATAI)
(Delayed Data from NSDQ)
$4.17 USD
+0.07 (1.71%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $4.18 +0.01 (0.24%) 7:58 PM ET
2-Buy of 5 2
F Value D Growth C Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ATAI 4.17 +0.07(1.71%)
Will ATAI be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ATAI based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ATAI
atai Life Sciences (ATAI) Upgraded to Strong Buy: Here's Why
Is atai Life Sciences (ATAI) Stock Outpacing Its Medical Peers This Year?
ATAI: What are Zacks experts saying now?
Zacks Private Portfolio Services
Are Medical Stocks Lagging atai Life Sciences (ATAI) This Year?
Are You Looking for a Top Momentum Pick? Why atai Life Sciences N.V. (ATAI) is a Great Choice
Is atai Life Sciences (ATAI) Stock Outpacing Its Medical Peers This Year?
Other News for ATAI
Oppenheimer Boosts Price Target for ATAI Life Sciences Due to Promising Prospects
Atai Life Sciences price target raised by $2 at Oppenheimer, here's why
Psychedelic stocks up after report on AbbVie-Gilgamesh deal talks
Psychedelic: Filament reports compassionate use approval for psilocybin
This IonQ Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday